ERAL1 and breast carcinoma: Randomized clinical studies within the adjuvant treatment framework, such as HERA, NSABP B-31, NCCTG N9831 and BCIRG 006, have also demonstrated how the addition of Trastuzumab to the typical therapy schemes has dramatically changed the natural history of HER2/neu+ breast cancer patients [40].